Suppr超能文献

关于心血管疾病相关氧化损伤与抗氧化保护的人体研究综述。

Review of human studies on oxidative damage and antioxidant protection related to cardiovascular diseases.

作者信息

Aviram M

机构信息

The Lipid Research Laboratory, Technion Faculty of Medicine, The Rappaport Family Institute for Research in the Medical Sciences and Rambam Medical Center, Haifa, Israel.

出版信息

Free Radic Res. 2000 Nov;33 Suppl:S85-97.

Abstract

Under oxidative stress, which is associated with atherosclerosis, oxidative modifications of LDL take place. A major effect of antioxidants in the LDL environment is to prevent the formation of oxidized LDL during atherogenesis. The question that arises is what are the body's capabilities to inhibit LDL oxidation and to remove and/or to neutralize atherogenic Ox-LDL when formed. Strategies to reduce LDL oxidation and atherogenesis can involve the enrichment of the LDL and arterial cells with potent antioxidants that can prevent oxidative damage to the arterial wall. There seems to be a clear cause and effect relationship between LDL oxidation and atherosclerosis. Atherosclerosis is a multifactorial disease and LDL is oxidized by all major cells of the arterial wall during the development of atherosclerosis via more than one mechanism. The various LDL oxidation pathways produce several lipid peroxidation products such as isoprostanes from arachidonic, eicosapentaenoic and docosahexaenoic acids, oxysterols from unesterified and esterified cholesterol, hydroxy fatty acids, lipid peroxides and aldehydes. Thus, one single assay of lipid peroxidation is probably not sufficient to serve as a marker for cardiovascular risk and there is a need for measurements of several markers. The use of biomarkers provides a logical scientific basis for major intervention trials of antioxidants; such trials will, in turn, eventually validate or disprove the biomarker concept. Any intervention trial that does take place should be accompanied by measurements of one or more relevant biomarkers at intervals during the study. If the endpoint of the trial is disease incidence or mortality, such studies will help to validate or disprove the biomarker concept. They might also help to explore the possibility that in vivo levels of oxidative lipid damage are early predictors of subsequent development of cardiovascular disease. In addition, specific antioxidants in serum, as well as serum paraoxonase activity can provide very useful information on the risk for cardiovascular diseases. For vascular disease risk, in addition to the markers in use for lipid peroxidation, there is a need to include also markers for endothelial dysfunction, monocyte adhesion, macrophage uptake of lipoproteins, thrombotic, and inflammatory processes.

摘要

在与动脉粥样硬化相关的氧化应激状态下,低密度脂蛋白(LDL)会发生氧化修饰。抗氧化剂在LDL环境中的主要作用是在动脉粥样硬化形成过程中防止氧化型LDL的形成。由此产生的问题是,当氧化型LDL形成时,身体抑制LDL氧化以及清除和/或中和致动脉粥样硬化的氧化型LDL的能力如何。降低LDL氧化和动脉粥样硬化的策略可包括用能防止动脉壁氧化损伤的强效抗氧化剂来富集LDL和动脉细胞。LDL氧化与动脉粥样硬化之间似乎存在明确的因果关系。动脉粥样硬化是一种多因素疾病,在动脉粥样硬化发展过程中,LDL会通过多种机制被动脉壁的所有主要细胞氧化。各种LDL氧化途径会产生多种脂质过氧化产物,如来自花生四烯酸、二十碳五烯酸和二十二碳六烯酸的异前列腺素、来自未酯化和酯化胆固醇的氧化甾醇、羟基脂肪酸、脂质过氧化物和醛类。因此,单一的脂质过氧化检测可能不足以作为心血管疾病风险的标志物,需要检测多种标志物。生物标志物的使用为抗氧化剂的主要干预试验提供了合理的科学依据;反过来,此类试验最终将验证或反驳生物标志物的概念。任何进行的干预试验都应在研究期间定期测量一种或多种相关生物标志物。如果试验的终点是疾病发病率或死亡率,此类研究将有助于验证或反驳生物标志物的概念。它们还可能有助于探索体内氧化脂质损伤水平是否是心血管疾病后续发展的早期预测指标。此外,血清中的特定抗氧化剂以及血清对氧磷酶活性可为心血管疾病风险提供非常有用的信息。对于血管疾病风险,除了现有的脂质过氧化标志物外,还需要纳入内皮功能障碍、单核细胞黏附、巨噬细胞摄取脂蛋白、血栓形成和炎症过程的标志物。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验